Castle Biosciences Raises Revenue Guidance on Strong Q2 Growth
Event summary
- Castle Biosciences reported Q2 2026 revenue of $103.5 million, up from $86.2 million in Q2 2025.
- Total test reports for core drivers (DecisionDx-Melanoma, TissueCypher) increased 32% YoY.
- Raised full-year 2026 revenue guidance to $365-375 million from $345-355 million.
- Expects positive Adjusted EBITDA for Q3, Q4, and full year 2026.
The big picture
Castle Biosciences' strong Q2 performance reflects growing clinical adoption of its diagnostic tests, particularly in dermatology and gastroenterology. The raised guidance suggests confidence in scaling operations while navigating regulatory changes. The company's focus on high-growth areas like atopic dermatitis positions it well in the personalized medicine market.
What we're watching
- Test Volume Growth
- Whether the 32% YoY increase in core test volumes can be sustained through the second half of 2026.
- Regulatory Impact
- How changes in Medicare coverage and state approvals will affect commercialization efforts for key tests.
- Profitability Transition
- The pace at which Castle Biosciences can achieve positive Adjusted EBITDA and maintain operational efficiency.
Related topics